Journal of Pharmaceutical Practice 2020;38(6):496-500

doi:10.12206/j.issn.1006-0111.202006061

Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists

Yanlan LAI 1 ; Aiwen HUANG 2 ; Lili ZHANG 2 ; Xiaolan LIAO 1 ; Lijun ZHAO 1 ; Hongtao SONG 2

Affiliations

+expand

Keywords

SGLT-2 inhibitors; GLP-1 receptor agonists; type 2 diabetes; cardiovascular safety

Country

China

Language

Chinese

Abstract

Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized.